Anterior Cruciate Ligament (ACL) injuries are prevalent in the United States and are associated with poor quality of life and decreased physical activity. Use of surgical intervention for the treatment of ACL injuries carries a myriad of challenges for patients including but not limited to high cost of treatment as well as an increased risk of developing secondary osteoarthritis. Given these difficulties associated with the application of surgical intervention in the treatment of acute ACL tears, more and more patients are looking for less invasive, cost-effective treatment modalities including the application of autologous stem cell treatment. While physicians have begun to offer more autologous stem cell treatment modalities to patients who have experienced acute ACL tears, there is still a lack of quality research that demonstrates the efficacy of these therapies, thus indicating the need for more thorough studies that evaluate the effectiveness of this regenerative orthobiologic technology. Bone Marrow Aspirate Concentrate has risen as a potential viable option for patients interested in regenerative, less invasive treatment of knee pathologies